Efficacy of ICIs, targeting in PD-1/PD-L1 axis, in NSCLC’s clinical treatment has been proved a lot, from second line to first line, even in early stage patients [8–12]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.